Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Al-Hajj

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Opinion in Oncology|November 30, 2006
Cancer stem cells and oncology therapeuticsMuhammad Al-Hajj
Oncogene|September 21, 2004
Self-renewal and solid tumor stem cellsMuhammad Al-Hajj, Michael F Clarke
Molecular Therapy. Methods & Clinical Development|August 25, 2023
Detection and quantification of integrated vector copy number by multiplex droplet digital PCR in dual-transduced CAR T cellsWei Wang, Muhammad Al-Hajj, Alireza S Alavi
Idrugs : the Investigational Drugs Journal|August 28, 2010
The ABCs of cancer stem cell drug resistanceAaron Elliott, Aaron Elliot, Jerry Adams, et al.
Current Opinion in Genetics & Development|April 28, 2004
Therapeutic implications of cancer stem cellsMuhammad Al-Hajj, Michael W Becker, Max Wicha, et al.
Cell Proliferation|October 3, 2003
Stem cells in normal breast development and breast cancerGabriela Dontu, Muhammad Al-Hajj, Wissam M Abdallah, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2003
Prospective identification of tumorigenic breast cancer cellsMuhammad Al-Hajj, Max S Wicha, Adalberto Benito-Hernandez, et al.
Molecular Cancer Research : MCR|July 13, 2016
Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor GrowthHeather Jackson, David Granger, Gavin Jones, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapyLydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, et al.
Nature Medicine|October 13, 2021
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trialShaun Cordoba, Shimobi Onuoha, Simon Thomas, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|November 30, 2006
Cancer stem cells and oncology therapeuticsMuhammad Al-Hajj
Oncogene|September 21, 2004
Self-renewal and solid tumor stem cellsMuhammad Al-Hajj, Michael F Clarke
Molecular Therapy. Methods & Clinical Development|August 25, 2023
Detection and quantification of integrated vector copy number by multiplex droplet digital PCR in dual-transduced CAR T cellsWei Wang, Muhammad Al-Hajj, Alireza S Alavi
Idrugs : the Investigational Drugs Journal|August 28, 2010
The ABCs of cancer stem cell drug resistanceAaron Elliott, Aaron Elliot, Jerry Adams, et al.
Current Opinion in Genetics & Development|April 28, 2004
Therapeutic implications of cancer stem cellsMuhammad Al-Hajj, Michael W Becker, Max Wicha, et al.
Cell Proliferation|October 3, 2003
Stem cells in normal breast development and breast cancerGabriela Dontu, Muhammad Al-Hajj, Wissam M Abdallah, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 12, 2003
Prospective identification of tumorigenic breast cancer cellsMuhammad Al-Hajj, Max S Wicha, Adalberto Benito-Hernandez, et al.
Molecular Cancer Research : MCR|July 13, 2016
Novel Bispecific Domain Antibody to LRP6 Inhibits Wnt and R-spondin Ligand-Induced Wnt Signaling and Tumor GrowthHeather Jackson, David Granger, Gavin Jones, et al.
Journal for Immunotherapy of Cancer|July 3, 2023
Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapyLydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, et al.
Nature Medicine|October 13, 2021
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trialShaun Cordoba, Shimobi Onuoha, Simon Thomas, et al.
Pageof 2